Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells have been recently described to localize to breast carcinomas, where they integrate into the tumour-associated stroma. However, the involvement of mesenchymal stem cells (or their derivatives) in tumour pathophysiology has not been addressed. Here, we demonstrate that bone-marrow-derived human mesenchymal stem cells, when mixed with otherwise weakly metastatic human breast carcinoma cells, cause the cancer cells to increase their metastatic potency greatly when this cell mixture is introduced into a subcutaneous site and allowed to form a tumour xenograft. The breast cancer cells stimulate de novo secretion of the chemokine CCL5 (also called RANTES) from mesenchymal stem cells, which then acts in a paracrine fashion on the cancer cells to enhance their motility, invasion and metastasis. This enhanced metastatic ability is reversible and is dependent on CCL5 signalling through the chemokine receptor CCR5. Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MSC can be mobilized and recruited to active tumor sites, where they can incorporate into the tumor’s microenvironment [5, 68, 100–103].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [100]
In the citing paper
“CCL5 can be secreted by both BM-MSC and ASC [100, 144] and displays pro-proliferative activities on breast cancer cell lines [145, 146].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [100]
In the citing paper
“Another MSC-secreted pro-metastasis cytokine, CCL5 (RANTES), can be secreted upon interaction with cancer cells and is associated with tumor progression and invasion in various cancers [73, 87, 100, 142–144].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [100]
In the citing paper
“The injection of bone marrow-derived MSCs into tumour-bearing mice has demonstrated that they can become CAFs40”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [40]
In the citing paper
“CAFs comprise the majority of cell types within the TME, and their reciprocal interactions with cancer cells have been well documented (Whiteside, 2008; Hazlehurst et al., 2003; Karnoub et al., 2007).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Karnoub et al., 2007
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Self-citationCreation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Self-citationCancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Self-citationHuman Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1874 · Cited by 1,035
(2002) · PubMed · Cited by 903
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., & Weinberg, R. A. (2001) · Genes & Development · doi:10.1101/gad.828901 · Cited by 878
Self-citation
Cited by
Items 301–400 of 1,024
Estrogen action and prostate cancer
Nelles, J. L., Hu, W.-Y., & Prins, G. S. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.11.20 · Cited by 214
Mesenchymal Stem Cell-Mediated Effects of Tumor Support or Suppression
Rhee, K.-J., Lee, J., & Eom, Y. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226215 · Cited by 214
“The ability of MSCs to promote tumor growth and metastasis was proved in a breast tumor mouse model [52] and similar results were also obtained from cancer cells co-implanted with MSCs [53–55].”
BackgroundResultInfluentialMesenchymal stem cells: Molecular characteristics and clinical applications
Sancricca, C. (2010) · World Journal of Stem Cells · doi:10.4252/wjsc.v2.i4.67 · Cited by 213
Shiozawa, Y., Havens, A. M., Pienta, K. J., & Taichman, R. S. (2008) · Leukemia · doi:10.1038/leu.2008.48 · Cited by 211
Nature meets nurture: molecular genetics of gastric cancer
Milne, A. N., Carneiro, F., O’Morain, C., & Offerhaus, G. J. A. (2009) · Human Genetics · doi:10.1007/s00439-009-0722-x · Cited by 211
Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate
Rosen, S. D., & Lemjabbar-Alaoui, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.504718 · Cited by 210
“5 [88] Invasive breast carcinoma stroma (53) vs normal (6) .”
BackgroundAnderson, P., Souza-Moreira, L., Morell, M., Caro, M., O'Valle, F., Gonzalez-Rey, E., & Delgado, M. (2013) · Gut · doi:10.1136/gutjnl-2012-302152 · Cited by 210
Goldstein, R. H., Reagan, M. R., Anderson, K., Kaplan, D. L., & Rosenblatt, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1254 · Cited by 210
“Because tumor growth does not necessarily correlate with metastatic outcome (3), we next investigated whether hBMSCs cocultured with BCCs could increase BCC migration in vitro or metastasis in vivo.”
The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma
Beck, A. H., Espinosa, I., Edris, B., Li, R., Montgomery, K., Zhu, S., Varma, S., Marinelli, R. J., van de Rijn, M., & West, R. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1283 · Cited by 210
Cancer Stem Cells and Targeting Strategies
Barbato, L., Bocchetti, M., Di Biase, A., & Regad, T. (2019) · Cells · doi:10.3390/cells8080926 · Cited by 209
Expression of α-Smooth Muscle Actin Determines the Fate of Mesenchymal Stromal Cells
Talele, N. P., Fradette, J., Davies, J. E., Kapus, A., & Hinz, B. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.05.004 · Cited by 209
“The most prominent examples are ‘‘cancerassociated fibroblasts’’ (CAFs) which originate at least in part from bone marrow-derived MSCs (Karnoub et al., 2007; Mishra et al., 2009; Öhlund et al., 2014; Quante et al., 2011).”
BackgroundCarcinoma‐associated fibroblasts: Non‐neoplastic tumour‐promoting mesenchymal cells
Polanska, U. M., & Orimo, A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24347 · Cited by 208
“…sulfate proteoglycan (NG2) (Sugimoto et al., 2006), platelet derived growth factor receptor-alpha/beta (PDGFRa/ b) (Pietras et al., 2003; Erez et al., 2010), fibroblast activation protein (FAP) (Kraman et al., 2010), palladin (Brentnall et al., 2012) and podoplanin (Kawase et al., 2008).”
BackgroundXu, W.-T., Bian, Z.-Y., Fan, Q.-M., Li, G., & Tang, T.-T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.022 · Cited by 206
“[17] showed that mesenchymal stem cells within tumor stroma promoted breast cancer metastasis.”
BackgroundTakaishi, S., Okumura, T., & Wang, T. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2603 · Cited by 206
Metastatic-niche labelling reveals parenchymal cells with stem features
Ombrato, L., Nolan, E., Kurelac, I., Mavousian, A., Bridgeman, V. L., Heinze, I., Chakravarty, P., Horswell, S., Gonzalez-Gualda, E., Matacchione, G., et al. (2019) · Nature · doi:10.1038/s41586-019-1487-6 · Cited by 206
Double‐edged sword of mesenchymal stem cells: Cancer‐promoting versus therapeutic potential
Lee, H., & Hong, I. (2017) · Cancer Science · doi:10.1111/cas.13334 · Cited by 204
Stem cells in cancer therapy: opportunities and challenges
Zhang, C.-L., Huang, T., Wu, B.-L., He, W.-X., & Liu, D. (2017) · Oncotarget · doi:10.18632/oncotarget.20798 · Cited by 203
“demonstrated that bone-marrow-derived MSCs mixed with otherwise weakly metastatic human breast carcinoma cells increased the cancer cells’ metastatic potentials, allowing for tumor formation in subcutaneous xenografts [75].”
BackgroundMicroRNA-125b Induces Metastasis by Targeting STARD13 in MCF-7 and MDA-MB-231 Breast Cancer Cells
Tang, F., Zhang, R., He, Y., Zou, M., Guo, L., & Xi, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035435 · Cited by 203
“[25] Markers are used to define the mesenchymal phenotype such as vimentin, a-SMA (smooth muscle alpha-actin),”
BackgroundRen, C., Kumar, S., Chanda, D., Kallman, L., Chen, J., Mountz, J. D., & Ponnazhagan, S. (2008) · Gene Therapy · doi:10.1038/gt.2008.101 · Cited by 202
Long, H., Xie, R., Xiang, T., Zhao, Z., Lin, S., Liang, Z., Chen, Z., & Zhu, B. (2012) · STEM CELLS · doi:10.1002/stem.1194 · Cited by 202
Gao, H., Priebe, W., Glod, J., & Banerjee, D. (2009) · Stem Cells · doi:10.1002/stem.23 · Cited by 202
Mesenchymal stem cells in tumor development: Emerging roles and concepts
Cuiffo, B. G., & Karnoub, A. E. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20875 · Cited by 201
“CCL5 then acts in a paracrine fashion on the cancer cells, fostering metastasis by increasing their ability to extravasate into lung parenchyma in experimental models.(21) Interestingly, not all cancer cells possessed the ability to instigate CCL5 from the MSCs, lending credence to the notion that idiosyncratic differ…”
BackgroundInfluentialSelf-citationKidd, S., Caldwell, L., Dietrich, M., Samudio, I., Spaeth, E. L., Watson, K., Shi, Y., Abbruzzese, J., Konopleva, M., Andreeff, M., et al. (2010) · Cytotherapy · doi:10.3109/14653241003631815 · Cited by 201
Obradovic, A., Graves, D., Korrer, M., Wang, Y., Roy, S., Naveed, A., Xu, Y., Luginbuhl, A., Curry, J., Gibson, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3570 · Cited by 200
Tumor cell behaviour modulation by mesenchymal stromal cells
Kucerova, L., Matuskova, M., Hlubinova, K., Altanerova, V., & Altaner, C. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-129 · Cited by 200
Luker, K. E., Lewin, S. A., Mihalko, L. A., Schmidt, B. T., Winkler, J. S., Coggins, N. L., Thomas, D. G., & Luker, G. D. (2012) · Oncogene · doi:10.1038/onc.2011.633 · Cited by 198
Kharaishvili, G., Simkova, D., Bouchalova, K., Gachechiladze, M., Narsia, N., & Bouchal, J. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-41 · Cited by 197
“Currently, no precise definition of CAFs exists because of the different cellular origin and markers expressed: CAFs are likely to derive from resident fibroblasts and marrow-derived mesenchymal precursor cells, whereas their generation through epithelial-mesenchymal transition (EMT) of tumor cells is more controversi…”
BackgroundWaterman, R. S., Henkle, S. L., & Betancourt, A. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045590 · Cited by 197
“Increases measured in the levels of CCL5 (RANTES) secreted by the pro-tumor MSC2 groups are in agreement with previous reports [8,13].”
ResultGM-CSF Mediates Mesenchymal–Epithelial Cross-talk in Pancreatic Cancer
Waghray, M., Yalamanchili, M., Dziubinski, M., Zeinali, M., Erkkinen, M., Yang, H., Schradle, K. A., Urs, S., Pasca Di Magliano, M., Welling, T. H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0947 · Cited by 197
“It has previously been reported that CA-MSCs (12, 13) and bone marrow MSCs (30) endow tumor cells with invasive and metastatic properties and thereby expedite tumor metastasis.”
BackgroundTu, B., Du, L., Fan, Q.-M., Tang, Z., & Tang, T.-T. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.06.006 · Cited by 196
Popp, F. C., Eggenhofer, E., Renner, P., Slowik, P., Lang, S. A., Kaspar, H., Geissler, E. K., Piso, P., Schlitt, H. J., & Dahlke, M. H. (2008) · Transplant Immunology · doi:10.1016/j.trim.2008.08.004 · Cited by 196
Takebe, N., Warren, R. Q., & Ivy, S. P. (2011) · Breast Cancer Research · doi:10.1186/bcr2876 · Cited by 195
“Weakly metastatic human breast cancer cells could be induced to form metastatic tumors in mice when mixed with bone marrow-derived mesenchymal stem cells [67].”
BackgroundAdvances in regenerative therapy: A review of the literature and future directions
Ntege, E. H., Sunami, H., & Shimizu, Y. (2020) · Regenerative Therapy · doi:10.1016/j.reth.2020.01.004 · Cited by 194
“BM-MSCs have been shown to increase tumorigenicity and invasiveness of breast cancer cells by inducing de novo expression of CCL5, a chemokine that acts in a paracrine manner to increase cell migration (in vitro) and extravascular translocation (in vivo) [206].”
BackgroundRose, A. A. N., Grosset, A.-A., Dong, Z., Russo, C., MacDonald, P. A., Bertos, N. R., St-Pierre, Y., Simantov, R., Hallett, M., Park, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1611 · Cited by 194
“higher GPNMB levels in tumor-associated stroma compared with that derived from normal breast (19, 29).”
BackgroundMolecular mechanisms and clinical management of cancer bone metastasis
Wang, M., Xia, F., Wei, Y., & Wei, X. (2020) · Bone Research · doi:10.1038/s41413-020-00105-1 · Cited by 193
“Another member of the chemokine superfamily, CCL5, is produced by BMDCs and local stem cells in the bone microenvironment, and together with its receptor CCR5, CCL5 enhances cancer bone metastases.(276,277) A recent report identified an increase in CCL5 secretion from bone stromal cells in the metastatic microenvironm…”
BackgroundFarnsworth, R. H., Lackmann, M., Achen, M. G., & Stacker, S. A. (2014) · Oncogene · doi:10.1038/onc.2013.304 · Cited by 193
The multifaceted role of mesenchymal stem cells in cancer
Timaner, M., Tsai, K. K., & Shaked, Y. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.003 · Cited by 193
Inhibition of KRAS -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit
Zhu, Z., Aref, A. R., Cohoon, T. J., Barbie, T. U., Imamura, Y., Yang, S., Moody, S. E., Shen, R. R., Schinzel, A. C., Thai, T. C., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0646 · Cited by 192
“CCL5-CCR5 signaling promotes chemotaxis and enhances metastasis of RAS-driven breast cancer cells (44).”
Qi, J., Zhou, Y., Jiao, Z., Wang, X., Zhao, Y., Li, Y., Chen, H., Yang, L., Zhu, H., & Li, Y. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479998 · Cited by 191
Xing, F., Kobayashi, A., Okuda, H., Watabe, M., Pai, S. K., Pandey, P. R., Hirota, S., Wilber, A., Mo, Y., Moore, B. E., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201623 · Cited by 190
“In this context, it is noteworthy that Karnoub et al reported that bone mesenchymal stem cells (BMSC) generate a ‘pre-metastatic niche’ at the distant organs even before metastatic cells arrive at the site (Karnoub et al, 2007).”
CCL2: An Important Mediator Between Tumor Cells and Host Cells in Tumor Microenvironment
Jin, J., Lin, J., Xu, A., Lou, J., Qian, C., Li, X., Wang, Y., Yu, W., & Tao, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722916 · Cited by 190
Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines
Durymanov, M. O., Rosenkranz, A. A., & Sobolev, A. S. (2015) · Theranostics · doi:10.7150/thno.11742 · Cited by 189
Drug targeting to myofibroblasts: Implications for fibrosis and cancer
Yazdani, S., Bansal, R., & Prakash, J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.010 · Cited by 189
Mechanisms of T-Cell Immunosuppression by Mesenchymal Stromal Cells: What Do We Know So Far?
Haddad, R., & Saldanha-Araujo, F. (2014) · BioMed Research International · doi:10.1155/2014/216806 · Cited by 188
“Interestingly, some surface markers have been associated with immunosuppressive capacity of MSCs. Stro-1 positive BM-MSCs inhibited PBMCs proliferation more efficiently than heterogeneous BM-MSCs [124].”
BackgroundBlocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression
Baglio, S. R., Lagerweij, T., Pérez-Lanzón, M., Ho, X. D., Léveillé, N., Melo, S. A., Cleton-Jansen, A.-M., Jordanova, E. S., Roncuzzi, L., Greco, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2726 · Cited by 187
“MSC-derived CCL5 promotes metastasis formation in breast and prostate cancer (9, 14), IL6 released by MSCs supports tumor growth and angiogenesis in colorectal cancer (15), and MSC-derived stromal-derived growth factor-1 (SDF-1) favors epithelial–mesenchymal transition (EMT) andmetastasis in prostate cancer (16).”
BackgroundPatrolling the vascular borders: platelets in immunity to infection and cancer
Gaertner, F., & Massberg, S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0202-z · Cited by 186
Neri, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102406 · Cited by 186
“Moreover, MSC ability to suppress immune responses may contribute to tumor growth promotion and metastasis of resident tumor cells [9,135,136].”
BackgroundMesenchymal stem cells in hematopoietic stem cell transplantation
Battiwalla, M., & Hematti, P. (2009) · Cytotherapy · doi:10.1080/14653240903193806 · Cited by 186
“Most concerning is the theoretical increased risk of relapse, now documented by Ning, et al in a single controlled trial, and tumor promoting effects demonstrated in several animal models [87,88].”
BackgroundLin, Y.-H., Chen, Y.-H., Chang, H.-Y., Au, H.-K., Tzeng, C.-R., & Huang, Y.-H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082385 · Cited by 186
“Bone marrow of healthy donor CD105+ CD31+ CD34− CD133− Increased tumor growth and metastasis Tumor increased BMMSC–secreted CCL-5 (RANTES) to increase cell motility, invasion, and metastasis [256]”
BackgroundVignais, M.-L., Caicedo, A., Brondello, J.-M., & Jorgensen, C. (2017) · Stem Cells International · doi:10.1155/2017/6917941 · Cited by 186
“The recruitment of MSCs to the tumor microenvironment depends on a number of cytokines and chemokines secreted by the tumor cells [105, 106] which can give rise to mutual cross talks between MSCs and cancer cells [102, 107].”
BackgroundMicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential
Wang, W. T., & Luo, Y. (2015) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1400184 · Cited by 186
“Understanding this key process in tumor initiation and metastasis may explain how CSCs form and suggest a possible avenue for their therapeutic manipulation (Karnoub et al., 2007; Mani et al., 2008; Scheel et al., 2011).”
BackgroundYan, X.-L., Jia, Y.-L., Chen, L., Zeng, Q., Zhou, J.-N., Fu, C.-J., Chen, H.-X., Yuan, H.-F., Li, Z.-W., Shi, L., et al. (2013) · Hepatology · doi:10.1002/hep.26257 · Cited by 185
“Recently, mesenchymal stem cells (MSCs), as a pivotal part of the tumor stroma, have attracted great attention for their ability to participate in tumor proliferation(3) and metastasis.(4) Although several lines of evidence demonstrate that MSCs can be activated by cancer cells and contribute to tumor progression, the”
Interaction of MSC with tumor cells
Melzer, C., Yang, Y., & Hass, R. (2016) · Cell Communication and Signaling · doi:10.1186/s12964-016-0143-0 · Cited by 185
“Similar functions are displayed by MSC during tumor development, whereby permanently proliferating and invasively growing tumor cells create an inflammatory microenvironment displaying a certain kind of “wound that never heals” [35].”
BackgroundInfluentialLiubomirski, Y., Lerrer, S., Meshel, T., Rubinstein-Achiasaf, L., Morein, D., Wiemann, S., Körner, C., & Ben-Baruch, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00757 · Cited by 184
Coherent anti-Stokes Raman scattering imaging of lipids in cancer metastasis
Le, T. T., Huff, T. B., & Cheng, J.-X. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-42 · Cited by 184
“Previous studies have also identified a number of other metastasis risk factors in tumour microenvironment including stem cells [27], fibroblasts [28], macrophages [29], collagen fibers [30], and others.”
BackgroundTargeting microRNAs as key modulators of tumor immune response
Paladini, L., Fabris, L., Bottai, G., Raschioni, C., Calin, G. A., & Santarpia, L. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0375-2 · Cited by 184
“MSCs are supposed to create a paracrine loop with cancer cells to induce cell invasion and migration, meanwhile monocytes act to promote the extravasation of tumor cells [101, 102].”
BackgroundKhan, S. A., Zhao, F., Goldstein, L. J., Cella, D., Basik, M., Golshan, M., Julian, T. B., Pockaj, B. A., Lee, C. A., Razaq, W., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02006 · Cited by 183
Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Kim, Y., Lin, Q., Glazer, P., & Yun, Z. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167113 · Cited by 183
MicroRNA‐183 regulates Ezrin expression in lung cancer cells
Wang, G., Mao, W., & Zheng, S. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.09.051 · Cited by 183
“23% (12/166) of up-regulated genes were functioning in cell adhesion, migration, invasion, and/or metastasis (Supplementary Table 2), including: CCL5, which enhanced motility, invasion, and metastasis of breast cancer cells through the chemokine receptor CCR5 [19]; CTHRC1, which promoted melanoma cells migration and w…”
BackgroundInfluentialMacrophages Associated with Tumors as Potential Targets and Therapeutic Intermediates
Vinogradov, S., Warren, G., & Wei, X. (2014) · Nanomedicine · doi:10.2217/nnm.14.13 · Cited by 182
Involvement of platelet‐derived growth factor ligands and receptors in tumorigenesis
Heldin, C. ‐., Lennartsson, J., & Westermark, B. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12690 · Cited by 181
Mesenchymal Stem Cells: Flip Side of the Coin
Mishra, P. J., Mishra, P. J., Glod, J. W., & Banerjee, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3562 · Cited by 181
“This suggests that hMSCs are a source of CAFs and can be used in modeling tumor-stroma interactions (17, 18).”
BackgroundSTC1 Expression By Cancer-Associated Fibroblasts Drives Metastasis of Colorectal Cancer
Peña, C., Céspedes, M. V., Lindh, M. B., Kiflemariam, S., Mezheyeuski, A., Edqvist, P.-H., Hägglöf, C., Birgisson, H., Bojmar, L., Jirström, K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1875 · Cited by 181
“Moreover, factors derived from cancer-associated fibroblasts (CAF) have been shown to promote metastasis (6).”
BackgroundVerginadis, I. I., Avgousti, H., Monslow, J., Skoufos, G., Chinga, F., Kim, K., Leli, N. M., Karagounis, I. V., Bell, B. I., Velalopoulou, A., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00918-8 · Cited by 181
Mesenchymal stem cells: A promising targeted-delivery vehicle in cancer gene therapy
Hu, Y.-L., Fu, Y.-H., Tabata, Y., & Gao, J.-Q. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.015 · Cited by 181
Tumor microenvironment: Bone marrow-mesenchymal stem cells as key players
Barcellos-de-Souza, P., Gori, V., Bambi, F., & Chiarugi, P. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.10.004 · Cited by 180
“BMMSC co-injected with cancer cells increased tumor growth in models of B16 melanoma [17,65], colon cancer [20,66], breast cancer [12,67], as well as in osteosarcoma [68], ovarian [21], colorectal [69,70], lung [17], gastric [34] and prostate carcinomas [24,25].”
BackgroundMesenchymal stem cells as a double-edged sword in tumor growth: focusing on MSC-derived cytokines
Liang, W., Chen, X., Zhang, S., Fang, J., Chen, M., Xu, Y., & Chen, X. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-020-00246-5 · Cited by 180
“CXCL1, CCL5, CXCL5, CXCL8 and CXCL7 [90, 174].”
BackgroundInfluentialTissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
Rothberg, B. E. G., Bracken, M. B., & Rimm, D. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp038 · Cited by 180
Picon-Ruiz, M., Pan, C., Drews-Elger, K., Jang, K., Besser, A. H., Zhao, D., Morata-Tarifa, C., Kim, M., Ince, T. A., Azzam, D. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0927 · Cited by 180
Shukla, L., Yuan, Y., Shayan, R., Greening, D. W., & Karnezis, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00158 · Cited by 179
Madeo, A., & Maggiolini, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0408 · Cited by 179
Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis
Mi, Z., Bhattacharya, S. D., Kim, V. M., Guo, H., Talbot, L. J., & Kuo, P. C. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr009 · Cited by 179
Klopp, A. H., Zhang, Y., Solley, T., Amaya-Manzanares, F., Marini, F., Andreeff, M., Debeb, B., Woodward, W., Schmandt, R., Broaddus, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1916 · Cited by 178
“In addition, recent studies demonstrate the capacity of MSC to induce the epithelial-tomesenchymal transition (EMT) in malignant cells and promote metastasis(14, 18).”
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J., & Piccart, M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 178
The Role of Breast Cancer Stem Cells in Metastasis and Therapeutic Implications
Velasco-Velázquez, M. A., Popov, V. M., Lisanti, M. P., & Pestell, R. G. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.03.005 · Cited by 178
“MSCs accumulate in the tumor and lung on intravenous injection in osteosarcoma-bearing mice.60 MSCs increase the rate of osteosarcoma lung metastasis via secretion of CCL5.”
BackgroundInfluentialEpithelial mesenchymal transition in drug resistance and metastasis of lung cancer
Nurwidya, F., Takahashi, F., Murakami, A., & Takahashi, K. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.3.151 · Cited by 177
“One view proposes that metastatic traits are acquired through exposure of epithelial cancer cells to paracrine signals received from mesenchymal cell types within the tumour-associated stroma [45].”
BackgroundCancer‐associated fibroblasts that restrain cancer progression: Hypotheses and perspectives
Miyai, Y., Esaki, N., Takahashi, M., & Enomoto, A. (2020) · Cancer Science · doi:10.1111/cas.14346 · Cited by 177
Sotgia, F., Martinez-Outschoorn, U. E., Pavlides, S., Howell, A., Pestell, R. G., & Lisanti, M. P. (2011) · Breast Cancer Research · doi:10.1186/bcr2892 · Cited by 177
“Th ey are not just neutral spectators, but actively support malignant transformation [28] and metastasis [29], as compared to normal resting fi broblasts.”
BackgroundCancer Stem Cells in Breast: Current Opinion and Future Challenges
Charafe-Jauffret, E., Monville, F., Ginestier, C., Dontu, G., Birnbaum, D., & Wicha, M. S. (2008) · Pathobiology · doi:10.1159/000123845 · Cited by 176
“Another strong demonstration of how tumor microenvironment in the breast facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells comes from Weinberg and colleagues [”
BackgroundCCL5 increases lung cancer migration via PI3K, Akt and NF-κB pathways
Huang, C.-Y., Fong, Y.-C., Lee, C.-Y., Chen, M.-Y., Tsai, H.-C., Hsu, H.-C., & Tang, C.-H. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.014 · Cited by 176
Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu
Rattigan, Y., Hsu, J.-M., Mishra, P. J., Glod, J., & Banerjee, D. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.07.002 · Cited by 176
Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Mohyeddin Bonab, M., Ali Sahraian, M., Aghsaie, A., Ahmadi Karvigh, S., Massoud Hosseinian, S., Nikbin, B., Lotfi, J., Khorramnia, S., Reza Motamed, M., Togha, M., et al. (2012) · Current Stem Cell Research & Therapy · doi:10.2174/157488812804484648 · Cited by 176
IL-6: The Link Between Inflammation, Immunity and Breast Cancer
Chen, J., Wei, Y., Yang, W., Huang, Q., Chen, Y., Zeng, K., & Chen, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903800 · Cited by 178
Salaudeen, M. A., Bello, N., Danraka, R. N., & Ammani, M. L. (2024) · Biomolecules · doi:10.3390/biom14030305 · Cited by 175
“Moreover, concerns about the safety of stem cell therapy persist, including the potential for teratoma formation and unintended tissue differentiation [106–108].”
BackgroundZhang, J., Hu, K., Di, L., Wang, P., Liu, Z., Zhang, J., Yue, P., Song, W., Zhang, J., Chen, T., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113964 · Cited by 175
Adipose tissue stem cells in regenerative medicine
Miana, V. V., & Prieto González, E. A. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.822 · Cited by 175
“It is also worth mentioning that the suicide gene therapy is based on sending inactive prodrugs together with cells modified to express transgenic enzymes that can modify the precursors, making them toxic in the tumour site [69].”
BackgroundThe multifaceted regulation and functions of PKM2 in tumor progression
Li, Z., Yang, P., & Li, Z. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.008 · Cited by 175
Mesenchymal Stem Cells Promote Formation of Colorectal Tumors in Mice
Tsai, K., Yang, S., Lei, Y., Tsai, C., Chen, H., Hsu, C., Chen, L., Wang, H., Miller, S. A., Chiou, S., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.045 · Cited by 175
Rowan, B. G., Gimble, J. M., Sheng, M., Anbalagan, M., Jones, R. K., Frazier, T. P., Asher, M., Lacayo, E. A., Friedlander, P. L., Kutner, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089595 · Cited by 174
Breast-cancer stem cells—beyond semantics
Badve, S., & Nakshatri, H. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70191-7 · Cited by 174
The effects of microenvironment in mesenchymal stem cell–based regeneration of intervertebral disc
Huang, Y.-C., Leung, V. Y. L., Lu, W. W., & Luk, K. D. K. (2013) · The Spine Journal · doi:10.1016/j.spinee.2012.12.005 · Cited by 174
“[134] Karnoub AE, Dash AB, Vo AP, et al.”
BackgroundProstaglandin E2/EP Signaling in the Tumor Microenvironment of Colorectal Cancer
Mizuno, R., Kawada, K., & Sakai, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246254 · Cited by 174
Bhagat, T. D., Von Ahrens, D., Dawlaty, M., Zou, Y., Baddour, J., Achreja, A., Zhao, H., Yang, L., Patel, B., Kwak, C., et al. (2019) · eLife · doi:10.7554/elife.50663 · Cited by 173
Klopp, A. H., Lacerda, L., Gupta, A., Debeb, B. G., Solley, T., Li, L., Spaeth, E., Xu, W., Zhang, X., Lewis, M. T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012180 · Cited by 173
“MSC have been shown to increase the growth of certain cancers when injected together with MSC and can increase the incidence of breast xenograft metastasis [15].”
BackgroundResultInfluentialTargeting tumor cell motility to prevent metastasis
Palmer, T. D., Ashby, W. J., Lewis, J. D., & Zijlstra, A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.04.008 · Cited by 173
“Tumor cells recruit mesenchymal stem cells which promote tumor cell motility through the production of CCL5 [72].”
BackgroundDong, L., Pu, Y., Zhang, L., Qi, Q., Xu, L., Li, W., Wei, C., Wang, X., Zhou, S., Zhu, J., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0323-5 · Cited by 173
Cuiffo, B. G., Campagne, A., Bell, G. W., Lembo, A., Orso, F., Lien, E. C., Bhasin, M. K., Raimo, M., Hanson, S. E., Marusyk, A., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.10.001 · Cited by 173
“Cells BCCs were cultured using standard protocols described elsewhere (Karnoub et al., 2007; El-Haibi et al., 2012).”
BackgroundMethodSelf-citationStewart, D. J. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.11.006 · Cited by 173
“, mediated by their stimulation of release f mesenchymal stem cells from the bone marrow [20]).”
Martinez-Outschoorn, U. E., Whitaker-Menezes, D., Pavlides, S., Chiavarina, B., Bonuccelli, G., Trimmer, C., Tsirigos, A., Migneco, G., Witkiewicz, A. K., Balliet, R. M., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.21.13817 · Cited by 155
The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression
Houthuijzen, J. M., Daenen, L. G. M., Roodhart, J. M. L., & Voest, E. E. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.201 · Cited by 153
“Additional experiments showed that tumour cells induced CCL5 expression in MSCs which in turn enhanced motility and invasion of the cancer cells (Karnoub et al, 2007).”
Background
Metadata
- Authors
- Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A.
- Affiliations
- Whitehead Institute for Biomedical Research (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Weinberg, Robert A.
- Venue
- Nature
- Published
- 2007-10-04
- Volume
- 449
- Issue
- 7162
- Pages
- 557-563
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2141815918
- Cited by
- 3,206
- References
- 36
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 95 · 2023: 137 · 2022: 144 · 2021: 186 · 2020: 192 · 2019: 153 · 2018: 145 · 2017: 176 · 2016: 182 · 2015: 222 · 2014: 232 · 2013: 232 · 2012: 216
- FWCI
- 89.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P50CA089393, R01CA116235)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Keywords
- mesenchymal stem cells, breast cancer metastasis, tumor stroma, RANTES, CCR5, paracrine signaling, tumor cell motility, tumor invasion, tumor microenvironment, bone marrow-derived stem cells, tumor xenografts
- MeSH terms
- Animals, Breast Neoplasms, Cell Movement, Fibroblasts, Humans, Lung Neoplasms, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Transplantation, Mice, SCID, Mice, Inbred NOD, Stromal Cells, Carcinoma, Ductal, Breast, Chemokine CCL5, Receptors, CCR5, Chemokines, CC, Paracrine Communication, Mesenchymal Stem Cell Transplantation, Cell Line, Tumor, Mice, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.